Controlled Substances Manufacturer; Application

Federal Register: March 19, 2008 (Volume 73, Number 54)

Notices

Page 14841

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr19mr08-90

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal

Regulations (CFR), this is notice that on February 29, 2008, Varian,

Inc., Lake Forest, 25200 Commercentre Drive, Lake Forest, California 92630-8810, made application by renewal to the Drug Enforcement

Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

Drug

Schedule

Phencyclidine (7471)....................... II 1-Piperidinocyclohexane- carbonitrile

II

(8603).

Benzoylecgonine (9180)..................... II

The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement

Administration, Office of Diversion Control, Federal Register

Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701

Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 19, 2008.

Dated: March 11, 2008.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug

Enforcement Administration.

FR Doc. E8-5532 Filed 3-18-08; 8:45 am

BILLING CODE 4410-09-P

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT